Cargando…
Low Bioavailability and High Immunogenicity of a New Brand of E. colil-Asparaginase with Active Host Contaminating Proteins
The drug l-asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). The native E. colil-asparaginase used in Brazil until recently has been manufactured by Medac/Kyowa. Then a decision was taken by the Ministry of Health in 2017 to supply the National Health System with...
Autores principales: | Zenatti, Priscila Pini, Migita, Natacha Azussa, Cury, Nathália Moreno, Mendes-Silva, Rosângela Aparecida, Gozzo, Fabio Cesar, de Campos-Lima, Pedro Otavio, Yunes, José Andrés, Brandalise, Silvia Regina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952248/ https://www.ncbi.nlm.nih.gov/pubmed/29550241 http://dx.doi.org/10.1016/j.ebiom.2018.03.005 |
Ejemplares similares
-
Molecular dynamic simulations of Escherichia colil-asparaginase to illuminate its role in deamination of asparagine and glutamine residues
por: Erva, Rajeswara Reddy, et al.
Publicado: (2015) -
Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center
por: Cecconello, Daiane Keller, et al.
Publicado: (2020) -
IGFBP7 Fuels the Glycolytic Metabolism in B-Cell Precursor Acute Lymphoblastic Leukemia by Sustaining Activation of the IGF1R–Akt–GLUT1 Axis
por: Artico, Leonardo Luís, et al.
Publicado: (2023) -
Colil: a database and search service for citation contexts in the life sciences domain
por: Fujiwara, Toyofumi, et al.
Publicado: (2015) -
Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing
por: Migita, Natacha Azussa, et al.
Publicado: (2023)